Recombinant human ErbB3 fragment vaccine (Zensun)

重组人纽表位肽

Report date: 2022/07/15 15:58:59

Base Information

Drug NameRecombinant human ErbB3 fragment vaccine (Zensun)
Drug Alias NameRecombinant human neu epitope peptide 12重组人纽表位肽12Therapeutic Tumour VaccinerhErbB3-f
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionReceptor tyrosine-protein kinase erbB-3 antagonistsReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZensun (Shanghai) Sci&Tech Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZensun (Shanghai) Sci&Tech Co Ltd
Inactive CompaniesShanghai Zesheng Pharmaceutical Co Ltd
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A